Virax Biolabs Group Ltd. delayed its 2025 Annual Meeting of Shareholders after failing to reach a quorum on March 11, 2026. The meeting, held at BioCity Glasgow, had only 15.74% of eligible shares represented, below the one-third quorum required under the company’s articles. The meeting was adjourned and reconvened on March 18, 2026. Although a one-third quorum still was not reached within 15 minutes, the company’s rules for an adjourned meeting allowed the shareholders present (15.78% of voting shares) to constitute a quorum, enabling the meeting to proceed. Shareholders approved all items put to a vote, including auditor ratification, the election of five directors, and proposals related to a share consolidation, amended articles, and a 2026 equity incentive plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-114283), on March 18, 2026, and is solely responsible for the information contained therein.